GRIMES & Co WEALTH MANAGEMENT LLC Reduces Position in Bristol Myers Squibb Company $BMY

Key Points

• GRIMES & Co WEALTH MANAGEMENT LLC reduced its stake in Bristol Myers Squibb by 7.5% in Q4, selling 28,024 shares and leaving 347,619 shares valued at about $18.75 million.
• BMY beat Q1 estimates with $1.58 EPS (vs. $1.42 expected) and $11.49B revenue, and set FY2026 guidance of 6.05–6.35 EPS (analysts forecast ~6.29 EPS).
• The company declared a quarterly dividend of $0.63 (annualized $2.52), implying a 4.5% yield and a payout ratio of about 70.8%.

GRIMES & Co WEALTH MANAGEMENT LLC cut its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 7.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 347,619 shares of the biopharmaceutical company's stock after selling 28,024 shares during the period. GRIMES & Co WEALTH MANAGEMENT LLC's holdings in Bristol Myers Squibb were worth $18,751,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in BMY. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter worth about $25,000. Physician Wealth Advisors Inc. lifted its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 202 shares in the last quarter. EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the 4th quarter valued at about $32,000. KERR FINANCIAL PLANNING Corp bought a new stake in Bristol Myers Squibb during the 3rd quarter valued at about $35,000. Finally, Garner Asset Management Corp bought a new stake in Bristol Myers Squibb during the 4th quarter valued at about $35,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Down 0.7%

NYSE:BMY opened at $56.18 on Friday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The firm has a market cap of $114.73 billion, a P/E ratio of 15.78, a P/E/G ratio of 0.16 and a beta of 0.26. The firm has a 50-day simple moving average of $59.28 and a 200-day simple moving average of $54.91.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same quarter in the previous year, the business posted $1.80 EPS. The company's quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.29 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.5%. Bristol Myers Squibb's payout ratio is currently 70.79%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BMY. Cantor Fitzgerald lifted their price objective on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a "neutral" rating in a report on Wednesday, April 8th. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They set a "sector perform" rating and a $60.00 price objective for the company. Wells Fargo & Company reiterated an "outperform" rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Bank of America decreased their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a report on Thursday, April 9th. Finally, Leerink Partners lifted their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an "outperform" rating in a report on Tuesday, January 13th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $61.31.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Zacks (covered on Yahoo Finance) highlights BMY as a top value stock for long‑term investors, emphasizing attractive style scores and dividend appeal that support buy‑and‑hold interest. Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
• Positive Sentiment: BMY is named in reports about BioNTech expanding pivotal oncology trials done in collaboration with Bristol Myers Squibb—this pipeline activity can boost long‑term revenue potential if trials progress. BioNTech Expands Oncology Trials And Reshapes Manufacturing As Investors Weigh Upside
• Positive Sentiment: BMY will participate at the Bank of America Securities Healthcare Conference, giving management a forum to reinforce guidance, pipeline timelines and commercialization plans—an opportunity to reassure investors. Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
• Neutral Sentiment: BMY launched a nationwide "Won't Lose" World Cup‑focused patient campaign to raise brand awareness; marketing may aid long‑term patient engagement but has limited immediate earnings impact. Bristol Myers Squibb World Cup Push Meets Valuation And Earnings Questions
• Neutral Sentiment: Analysts’ Q1 call questions (MSN recap) show market attention on growth drivers and margin dynamics—such scrutiny can amplify short‑term volatility even when fundamentals are intact. Bristol-Myers Squibb’s Q1 earnings call: Our top 5 analyst questions
• Neutral Sentiment: Commentary questioning whether BMY still offers value after a ~25% one‑year share gain highlights investor debate over valuation vs. yield; this may encourage profit taking. Is Bristol Myers Squibb (BMY) Offering Value After A 25.7% One Year Share Price Gain

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company's stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.